Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 98

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 98
---
 options to consultants and certain investors to be issued upon the completion of this offering under 
 our incentive option plan, at an exercise price of NIS 0.004;                                                                      |

| ● | 140,000 Ordinary Shares underlying warrants issuable to 
 the Bridge Loan lenders;                                |

| ● | 61,539 Ordinary Shares underlying warrants issuable to 
 the 2024 Loan Agreements lenders;                      |

| ● | 55,224 Ordinary Shares underlying warrants issuable to 
 the Company’s chief executive officer; and             |

| ● | 92,309 Ordinary Shares underlying warrants issuable to 
 lenders under the 2025 Loan Agreements.                |

<div align='center'>60

DILUTION</div>

If you invest in our Ordinary
Shares in this offering, your interest will be immediately diluted to the extent of the difference between the initial public offering
price per Ordinary Share sold in this offering and the pro forma as adjusted net tangible book value per Ordinary Share after this offering.
Dilution results from the fact that the initial public offering price per Ordinary Share is substantially in excess of the net tangible
book value per Ordinary Share. As of December 31, 2024, we had a historical net tangible book value of $(6,006) thousands, or $(37.03) per
Ordinary Share. Our net tangible book value per share represents total tangible assets less total liabilities, divided by 162,198 which
was the number of Ordinary Shares outstanding on December 31, 2024.

Our pro forma net tangible book
value as of December 31, 2024 was $(1,474) thousands, or $(0.37) per Ordinary Share. Pro forma net tangible book value per share represents
total tangible assets less total liabilities, divided by which is the number of Ordinary Shares outstanding as of December 31, 2024, after
giving effect to the following events as if each event had occurred on December 31, 2024: (i) the issuance of 2,603,652 Ordinary Shares
upon the automatic conversion of the 2,603,652 Preferred Shares issued and outstanding as of the date hereof, which will automatically
convert upon the completion of this offering at a 1:1 ratio; (ii) the issuance of 609,888 Ordinary Shares upon the automatic conversion
of the $900,000 outstanding principal of 2020 CLAs, which will occur upon the completion of this offering; (iii) the